ArticleTranslational pediatrics2026
The global landscape of pediatric hyperuricemia research: a bibliometric roadmap to mechanisms, management, and future therapeutics (1997-2024).
Article in Translational pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pediatric hyperuricemia has emerged as a significant global health concern, intricately linked to the early pathogenesis of metabolic syndrome, cardiovascular disease, and chronic kidney disease. Despite extensive research in adults, critical gaps persist in our understanding of its unique pathophysiology, age-specific diagnostic criteria, and evidence-based management strategies in children. This study aims to provide a comprehensive, quantitative assessment of the global research landscape on pediatric hyperuricemia, identify pivotal thematic foci, and map emerging frontiers to guide future scientific inquiry and clinical translation. Methods: We conducted a systematic bibliometric and visual analysis of all relevant articles and reviews indexed in the Web of Science Core Collection (WoS CC) from inception to December 20, 2024. Data were synthesized using VOSviewer, CiteSpace, and the Bibliometrix R package to construct collaboration networks, perform co-citation analyses, and track keyword evolution. Results: Our analysis identified 189 publications, revealing a trajectory of fluctuating but overall increasing scholarly attention. China (n=47) and the United States (n=43) were the most prolific contributors, with St. Jude Children's Research Hospital and Harvard University leading institutional output. Authors Simonetta Genovesi and Marco Giussani were the most productive. Keyword co-occurrence analysis delineated three dominant research clusters: (I) core clinical management ("hyperuricemia", "allopurinol", "rasburicase"); (II) cardiometabolic comorbidities ("obesity", "hypertension", "metabolic syndrome"); and (III) epidemiological and risk factor profiling ("children", "uric acid", "prevalence"). Notably, recent years have witnessed an emergent focus on long-term sequelae, including "chronic kidney disease" and "acute kidney injury". Conclusions: Research into pediatric hyperuricemia remains nascent yet is rapidly gaining momentum. Our roadmap highlights four critical frontiers: elucidating developmental-stage-specific pathological mechanisms, establishing validated diagnostic thresholds, evaluating the long-term safety and efficacy of both pharmacological and non-pharmacological interventions, and defining strategies for lifelong management to mitigate adult-onset complications. We advocate for enhanced international and interdisciplinary collaboration as the cornerstone for accelerating progress in this vital field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.